FAQs
What are the benefits of ACP Max compared to other PRP treatment systems?
ACP Max offers several advantages over standard PRP systems, including higher platelet concentrations (up to 12× baseline), a dual-spin centrifugation process for optimized purity, and up to 98.9% neutrophil reduction.1-3 It also enables the delivery of autologous, platelet-derived exosomes, which support tissue regeneration and anti-inflammatory effects.4 Its closed, sterile, triple-syringe design ensures safe, efficient preparation and immediate clinical use.
What are autologous exosomes?
Autologous exosomes are small extracellular vesicles (ranging from 30 to 200 nanometers) that are naturally present in platelet-rich plasma (PRP) formulations derived from a patient's own blood. These vesicles play a key role in intercellular communication by transporting proteins, lipids, microRNA (miRNA) and nucleic acids between cells.10 In the context of aesthetic medicine, autologous exosomes—specifically those derived from platelets—are believed to contribute to tissue repair, regeneration, and anti-inflammatory effects,5, 9 making them valuable in treatments for wounds, scars, and other skin conditions.5-8
How safe is the application of autologous exosomes?
The application of autologous exosomes—such as those present in ACP Max PRP—is considered safe in aesthetic medicine. Because these exosomes are derived from the patient’s own blood, they are autologous and biocompatible, which significantly reduces the risk of immune or adverse reactions.
What are the benefits of highly concentrated PRP?
Highly concentrated PRP—such as that produced by the ACP Max system—contains significantly elevated levels of platelets, growth factors, and platelet-derived exosomes, which enhance the body’s natural healing and regenerative processes. This concentration supports more effective tissue repair, reduces inflammation, and promotes better outcomes in aesthetic applications like skin rejuvenation and scar treatment. Additionally, when neutrophils are minimized, as in ACP Max, the risk of unwanted inflammation is further reduced.1-3
What is the source of the exosomes in ACP Max?
The exosomes included in ACP Max are autologous and platelet-derived, meaning they originate from the patient’s own blood and are naturally present in the highly concentrated platelet-rich plasma (PRP) produced by the system. These exosomes are released by platelets during the PRP preparation process and are retained through ACP Max’s dual-spin centrifugation method, which is designed to preserve regenerative components like platelets and their associated exosomes.
What is the difference between platelet-derived and plant-derived exosomes?
Platelet-derived exosomes are sourced from a patient’s own blood, making them autologous, highly biocompatible, and well-suited for use in regenerative and aesthetic medicine.5, 7 In contrast, plant-derived exosomes—often referred to as exosome-like vesicles—are extracted from plant cells and offer a non-animal alternative, though their lack of natural presence in the human body may limit their integration and therapeutic effectiveness.8 Platelet-derived exosomes are rich in growth factors, peptides, nucleic acids, and signaling molecules that actively support tissue repair, inflammation modulation, and regeneration.4,6,9 Plant-derived exosomes, while containing antioxidants and plant-specific bioactive compounds, have less consistent regenerative potency and their effects can vary depending on the plant source and extraction method.8
What is a buffy coat system?
A buffy coat system is a type of platelet-rich plasma (PRP) preparation method that targets the buffy coat layer—a thin, concentrated layer of white blood cells (WBCs) and platelets that forms between the red blood cells and plasma after blood is centrifuged. The ACP Max PRP system is designed to partially include the buffy coat by stopping plasma extraction just above it during processing. This approach allows for the collection of platelets while minimizing the inclusion of white blood cells, particularly neutrophils, which are known to contribute to inflammation and pain. As a result, the ACP Max system produces a leukocyte-reduced PRP with a higher concentration of platelets in a smaller volume, making it a targeted and efficient option for applications where reduced inflammation is desired.11






